Genomic landscape of stage 0–IA lung adenocarcinoma identified by on-site reflex targeted NGS

Key Points

• Stage 0–IA lung adenocarcinoma has a unique genomic landscape, providing essential insights into early disease.
• Key evidence shows that targeted next-generation sequencing (NGS) identified specific molecular pathways in 85% of samples.
• Analysis of genomic data utilized on-site reflex targeted NGS to detect critical biomarkers for cancer progression.
• Highlights the need for further development in early-stage lung cancer diagnostics using advanced genomic techniques.